

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION		
10/574,135	10/18/2006	Amar Lulla	PAC/23225 US (4137-00600)	8688	
CONLEY RO	7590 06/13/201 SE P C	EXAM	EXAMINER		
5601 GRANIT	E PARKWAY, SUITE	WESTERBERG, NISSA M			
PLANO, TX 7	5024		ART UNIT	PAPER NUMBER	
			1618		
			MAIL DATE	DELIVERY MODE	
			06/13/2011	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)	
		LULLA ET AL.	
		Art Unit	
		1618	

		NIS	SA WESTERBERG	1618					
The MA	ALLING DATE of this communication appe	ars c	on the cover sheet with the c	correspondence address					
THE REPLY FILED	01 June 2011 FAILS TO PLACE THIS APP	LICA	TION IN CONDITION FOR A	LLOWANCE.					
application, a application in	filed after a final rejection, but prior to or on pplicant must timely file one of the following condition for allowance; (2) a Notice of Appe Examination (RCE) in compliance with 37 C	replie eal (w	es: (1) an amendment, affidavi vith appeal fee) in compliance	t, or other evidence, which places the with 37 CFR 41.31; or (3) a Request					
b) The period no event, I Examiner	I for reply expiresmonths from the mailing I for reply expires on; (1) the mailing date of this Autorovever, will the statutory period for reply expire la Note: If box 1 is checked, check either box (a) or (i	dviso ater th	ry Action, or (2) the date set forth an SIX MONTHS from the mailing	date of the final rejection.					
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). ktensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee									
have been filed is the under 37 CFR 1.17(a) set forth in (b) above,	date for purposes of determining the period of ext is calculated from: (1) the expiration date of the s if checked. Any reply received by the Office later ad patent term adjustment. See 37 CFR 1.704(b).	tensio shorte than	n and the corresponding amount on ned statutory period for reply origi	of the fee. The appropriate extension fee nally set in the final Office action; or (2) as					
filing the Noti	Appeal was filed on A brief in compose of Appeal (37 CFR 41.37(a)), or any exterposal has been filed, any reply must be filed	nsion	thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since					
	dd								
(a) 🔲 They ra	d amendment(s) filed after a final rejection, but ise new issues that would require further cor- ise the issue of new matter (see NOTE below	nside							
(c) 🔲 They ar	e not deemed to place the application in bett and/or		rm for appeal by materially red	ducing or simplifying the issues for					
(d) They p	esent additional claims without canceling a c	corre	sponding number of finally reje	ected claims.					
	ents are not in compliance with 37 CFR 1.12	21. S	ee attached Notice of Non-Co	mpliant Amendment (PTOL-324).					
5. 🔲 Applicant's r	eply has overcome the following rejection(s):	:							
 Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling non-allowable claim(s). 									
how the new	of appeal, the proposed amendment(s): a) [or amended claims would be rejected is prov the claim(s) is (or will be) as follows:			I be entered and an explanation of					
Claim(s) allow									
Claim(s) obje	cted to:								
	ted: <u>1-8,11-14,18-33 and 53</u> .								
	drawn from consideration: 9 and 10.								
AFFIDAVIT OR OT	nen evidence or other evidence filed after a final action, but	t hafa	ero or on the data of filing a No	ation of Annual will not be entered					
because appl	icant failed to provide a showing of good and er presented. See 37 CFR 1.116(e).								
D. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CPR 41.33(d)(1).									
0. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.									
REQUEST FOR RECONSIDERATION/OTHER									
 The request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet.</u> 									
2. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).									
13. Cther:									
			/Nissa M Westerberg/ Primary Examiner, Art U	nit 1618					

Continuation of 11, does NOT place the application in condition for allowance because: The rejection of claims 1 - 8, 11 - 22, 25 - 32 and 53 under 35 U.S.C. 103(a) as being unpatentable over Katdare et al. (WO 95/29679) in view of Adamski et al. (WO 01/85176) is maintained for the reasons of record set forth in the Office Action mailed April 5, 2011 and those set forth below.

The claim amendment imports the limitation from dependent claim 54 into independent claim 1.

Applicants traverse this rejection on the grounds that the limitation of the carbohydrate alcohol being between 15 kt. % and 40 kt. % of the formulation is not taught by the applied references. Only Adamski discloses the use of a specific amount of orbydrate alcohol as the range of diluent encompassed by the combination is 30 - 80% (arguendo). The amount of carbohydrate alcohol in Adamski discloses a range of manulot of 50-80%, which is outside the presently claimed range. The statement in the previous Office Action about lower amounts of mannitol being used when a second diluent is present is conclusory and that Adamski does not reduce the amount of mannitol in the previous Office.

These arguments are unpersuasive. The range of mannitol set forth in Adamski is only a preferred range (p 6, In 19) and the amounts of the various ingredients in the pharmaceutical composition are a results effective parameter that the person of ordinary skill in the art would routiney obtainize (see o 3 - 4 of previous Office Action). The criticality of this range has not established by Apolenant.

The rejections of claims 23, 24 and 33 as being unpatentable over Katdare and Adamski further in view of Flash-Ner-Barak et al. (WO 2002/00204) is not argued by Applicant and thus is maintained for the reasons set forth above in regards to Adamski and Katdare above and for the reasons of record set forth in the Office Action mailed April 5, 2011.